Kura Oncology Q2 EPS Decreased by Brookline Capital Markets

Kura Oncology, Inc. (NASDAQ:KURA) – Stock analysts at Brookline Capital Markets decreased their Q2 2026 earnings per share estimates for shares of Kura Oncology in a note issued to investors on Friday, May 22nd. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of ($1.02) for the quarter, down from their prior estimate of ($0.84). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.23) per share. Brookline Capital Markets also issued estimates for Kura Oncology’s Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($3.65) EPS, FY2027 earnings at ($2.54) EPS, FY2028 earnings at ($2.38) EPS, FY2029 earnings at $6.01 EPS and FY2030 earnings at $18.49 EPS.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.05. The business had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%.

A number of other brokerages have also recently issued reports on KURA. UBS Group reissued a “buy” rating and set a $15.00 price target (down from $16.00) on shares of Kura Oncology in a research report on Friday, March 13th. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Tuesday, April 21st. Finally, Mizuho decreased their price target on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, March 24th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.38.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $10.41 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15. The firm has a market cap of $924.14 million, a PE ratio of -3.11 and a beta of 0.32. Kura Oncology has a fifty-two week low of $5.45 and a fifty-two week high of $12.49. The business has a 50 day moving average price of $9.09 and a 200-day moving average price of $9.46.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently modified their holdings of the company. Rhumbline Advisers lifted its position in shares of Kura Oncology by 0.9% in the third quarter. Rhumbline Advisers now owns 119,935 shares of the company’s stock valued at $1,061,000 after acquiring an additional 1,039 shares in the last quarter. IFP Advisors Inc boosted its position in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after acquiring an additional 1,284 shares during the last quarter. Royal Bank of Canada grew its stake in Kura Oncology by 7.6% during the fourth quarter. Royal Bank of Canada now owns 19,577 shares of the company’s stock valued at $203,000 after acquiring an additional 1,375 shares in the last quarter. Allworth Financial LP lifted its stake in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after purchasing an additional 1,553 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC boosted its holdings in shares of Kura Oncology by 7.9% during the 4th quarter. Focus Partners Advisor Solutions LLC now owns 22,889 shares of the company’s stock valued at $238,000 after purchasing an additional 1,682 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.